Nonalcoholic Fatty Liver Disease and Sarcopenia: Where Do We Stand?

Overview

Journal Can J Gastroenterol Hepatol

Specialty Gastroenterology

Date 2020 Nov 18

PMID 33204675

Citations 10

Authors

Ivana Mikolasevic

Tajana Pavic

Tajana Filipec Kanizaj

Darija Vranesic Bender

Viktor Domislovic

Zeljko Krznaric

Affiliations

Soon will be listed here.

Abstract

The link between metabolic syndrome (MetS) and sarcopenia has not been extensively studied, but it is evident that they share several common features. Crucial mechanisms involved in sarcopenia-nonalcoholic fatty liver disease (NAFLD) interplay are based on effects of insulin resistance, chronic inflammation, oxidative stress, and crosstalk between organs by secretion of cytokines (hepatokines, adipokines, and myokines). Currently, published studies confirm the association of sarcopenia with the degree of NAFLD defined by liver histology. However, prospective studies that will give us information regarding the causal effect of NAFLD and sarcopenia are still needed. Furthermore, there is a need for a patient-friendly, noninvasive, low-cost method for detection of loss of skeletal muscle mass, strength, and physical performance in the context of NAFLD. Moreover, potential treatment strategies such as physical exercise and nutritional supplementation, that are usually a part of management of sarcopenia, should also be investigated in NAFLD patients, especially given the fact that for now, we do not have a good treatment option for NAFLD. Therefore, future investigations should combine studies on NAFLD and sarcopenia in terms of physical activity and nutritional interventions such as vitamin D supplementation. This review aims to report recent evidence concerning the links between sarcopenia and NAFLD and methods to assess sarcopenia.

Citing Articles

Assessment of skeletal muscle alterations and circulating myokines in metabolic dysfunction-associated steatotic liver disease: A cross-sectional study.

Real Martinez Y, Fernandez-Garcia C, Fuertes-Yebra E, Calvo Soto M, Berlana A, Barrios V World J Gastroenterol. 2025; 31(7):100039.

PMID: 39991673 PMC: 11755261. DOI: 10.3748/wjg.v31.i7.100039.

Causal relationship between non-alcoholic fatty liver disease and sarcopenia: a bidirectional Mendelian randomization study.

Chen M, Liu J, Xia X, Wang Y, Zheng H Front Med (Lausanne). 2024; 11:1422499.

PMID: 39359931 PMC: 11445014. DOI: 10.3389/fmed.2024.1422499.

Adipokines in the Crosstalk between Adipose Tissues and Other Organs: Implications in Cardiometabolic Diseases.

Hemat Jouy S, Mohan S, Scichilone G, Mostafa A, Mahmoud A Biomedicines. 2024; 12(9).

PMID: 39335642 PMC: 11428859. DOI: 10.3390/biomedicines12092129.

The Roles of Non-Pharmacologic and Emerging Pharmacologic Management of Non-alcoholic Fatty Liver Disease and Sarcopenia: A Narrative Review.

Rivera F, Adizas A, Cubarrubias D, Bantayan N, Choi S, Carado G J ASEAN Fed Endocr Soc. 2024; 39(1):84-94.

PMID: 38863907 PMC: 11163315. DOI: 10.15605/jafes.039.01.04.

ADAR2 deficiency ameliorates non-alcoholic fatty liver disease and muscle atrophy through modulating serum amyloid A1.

Kung M, Yang T, Lin C, Ho J, Hung T, Chang C J Cachexia Sarcopenia Muscle. 2024; 15(3):949-962.

PMID: 38533529 PMC: 11154747. DOI: 10.1002/jcsm.13460.

References

Kobayashi K, Maruyama H, Kiyono S, Ogasawara S, Suzuki E, Ooka Y . Application of transcutaneous ultrasonography for the diagnosis of muscle mass loss in patients with liver cirrhosis. J Gastroenterol. 2017; 53(5):652-659. DOI: 10.1007/s00535-017-1378-2. View

Aubrey J, Esfandiari N, Baracos V, Buteau F, Frenette J, Putman C . Measurement of skeletal muscle radiation attenuation and basis of its biological variation. Acta Physiol (Oxf). 2014; 210(3):489-97. PMC: 4309522. DOI: 10.1111/apha.12224. View

Larsen B, Allison M, Laughlin G, Araneta M, Barrett-Connor E, Wooten W . The association between abdominal muscle and type II diabetes across weight categories in diverse post-menopausal women. J Clin Endocrinol Metab. 2014; 100(1):E105-9. PMC: 4283010. DOI: 10.1210/jc.2014-2839. View

Peng T, Wu L, Chen W, Liaw F, Chang Y, Kao T . Nonalcoholic fatty liver disease and sarcopenia in a Western population (NHANES III): The importance of sarcopenia definition. Clin Nutr. 2017; 38(1):422-428. DOI: 10.1016/j.clnu.2017.11.021. View

Tandon P, Low G, Mourtzakis M, Zenith L, Myers R, Abraldes J . A Model to Identify Sarcopenia in Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2016; 14(10):1473-1480.e3. DOI: 10.1016/j.cgh.2016.04.040. View

Kim B, Ahn S, Lee S, Hong S, Hamrick M, Isales C . Lower hand grip strength in older adults with non-alcoholic fatty liver disease: a nationwide population-based study. Aging (Albany NY). 2019; 11(13):4547-4560. PMC: 6660042. DOI: 10.18632/aging.102068. View

Hong H, Hwang S, Choi H, Yoo H, Seo J, Kim S . Relationship between sarcopenia and nonalcoholic fatty liver disease: the Korean Sarcopenic Obesity Study. Hepatology. 2013; 59(5):1772-8. DOI: 10.1002/hep.26716. View

Chen L, Woo J, Assantachai P, Auyeung T, Chou M, Iijima K . Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. J Am Med Dir Assoc. 2020; 21(3):300-307.e2. DOI: 10.1016/j.jamda.2019.12.012. View

Park S, Goodpaster B, Lee J, Kuller L, Boudreau R, de Rekeneire N . Excessive loss of skeletal muscle mass in older adults with type 2 diabetes. Diabetes Care. 2009; 32(11):1993-7. PMC: 2768193. DOI: 10.2337/dc09-0264. View

10.

Guillet C, Boirie Y . Insulin resistance: a contributing factor to age-related muscle mass loss?. Diabetes Metab. 2006; 31 Spec No 2:5S20-5S26. DOI: 10.1016/s1262-3636(05)73648-x. View

11.

Janssen I, Heymsfield S, Ross R . Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. J Am Geriatr Soc. 2002; 50(5):889-96. DOI: 10.1046/j.1532-5415.2002.50216.x. View

12.

Newman A, Kupelian V, Visser M, Simonsick E, Goodpaster B, Nevitt M . Sarcopenia: alternative definitions and associations with lower extremity function. J Am Geriatr Soc. 2003; 51(11):1602-9. DOI: 10.1046/j.1532-5415.2003.51534.x. View

13.

Janssen I, Baumgartner R, Ross R, Rosenberg I, Roubenoff R . Skeletal muscle cutpoints associated with elevated physical disability risk in older men and women. Am J Epidemiol. 2004; 159(4):413-21. DOI: 10.1093/aje/kwh058. View

14.

Cruz-Jentoft A, Landi F, Schneider S, Zuniga C, Arai H, Boirie Y . Prevalence of and interventions for sarcopenia in ageing adults: a systematic review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS). Age Ageing. 2014; 43(6):748-59. PMC: 4204661. DOI: 10.1093/ageing/afu115. View

15.

Zhai Y, Xiao Q, Miao J . The Relationship between NAFLD and Sarcopenia in Elderly Patients. Can J Gastroenterol Hepatol. 2018; 2018:5016091. PMC: 5892294. DOI: 10.1155/2018/5016091. View

16.

Berzigotti A, Abraldes J . Impact of obesity and insulin-resistance on cirrhosis and portal hypertension. Gastroenterol Hepatol. 2013; 36(8):527-33. DOI: 10.1016/j.gastrohep.2013.03.005. View

17.

Golse N, Bucur P, Ciacio O, Pittau G, Sa Cunha A, Adam R . A new definition of sarcopenia in patients with cirrhosis undergoing liver transplantation. Liver Transpl. 2017; 23(2):143-154. DOI: 10.1002/lt.24671. View

18.

Cawthon P, Peters K, Shardell M, McLean R, Dam T, Kenny A . Cutpoints for low appendicular lean mass that identify older adults with clinically significant weakness. J Gerontol A Biol Sci Med Sci. 2014; 69(5):567-75. PMC: 3991141. DOI: 10.1093/gerona/glu023. View

19.

Zhang H, Zhang X, Ma Z, Pan L, Chen Z, Han H . Irisin is inversely associated with intrahepatic triglyceride contents in obese adults. J Hepatol. 2013; 59(3):557-62. DOI: 10.1016/j.jhep.2013.04.030. View

20.

Wang C, Feng S, Covinsky K, Hayssen H, Zhou L, Yeh B . A Comparison of Muscle Function, Mass, and Quality in Liver Transplant Candidates: Results From the Functional Assessment in Liver Transplantation Study. Transplantation. 2016; 100(8):1692-8. PMC: 4962324. DOI: 10.1097/TP.0000000000001232. View